HGSI Post-ER Charts
Analyst calls Human Genome sell-off "overdone"
In a note to investors Friday, Leerink Swann analyst Joseph Schwartz said that the current sell-off of shares of Human Genome Sciences (HGSI) was "overdone." Investors pushed down shares of the biotech group by almost 8% to $21.28 Friday on concerns that quarterly sales of the company's new lupus drug Benlysta were weaker than expected. "We believe today's Human Genome stock weakness is overdone, misplaced and likely a knee-jerk reaction to the headline 'miss' last night after the close," wrote Schwartz. "In fact including $1.2 million stocking, as some companies would report the numbers, Benlysta sales (plus deferred sales) actually beat expectations. We think the numbers going forward are very achievable and would use weakness as buying opportunity," Schwartz added.
As of 7-22-2011
Analyst calls Human Genome sell-off "overdone"
In a note to investors Friday, Leerink Swann analyst Joseph Schwartz said that the current sell-off of shares of Human Genome Sciences (HGSI) was "overdone." Investors pushed down shares of the biotech group by almost 8% to $21.28 Friday on concerns that quarterly sales of the company's new lupus drug Benlysta were weaker than expected. "We believe today's Human Genome stock weakness is overdone, misplaced and likely a knee-jerk reaction to the headline 'miss' last night after the close," wrote Schwartz. "In fact including $1.2 million stocking, as some companies would report the numbers, Benlysta sales (plus deferred sales) actually beat expectations. We think the numbers going forward are very achievable and would use weakness as buying opportunity," Schwartz added.
As of 7-22-2011
My post is for my entertainment, do your own DD before pushing your
buy/sell buttons
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
